Karl Griswold

Research Interests

Protein engineering; directed evolution; biotherapeutics; applied biocatalysis; high throughput screening

Education

• BS, Chemistry, Southwest Texas State University 1995
• PhD, Chemistry, University of Texas at Austin 2005

Awards

• Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008)
• NIH Biotechnology Training Grant (2000-2003)
• Royston M. Roberts - Regents Fellowship, University of Texas (1999)
• DOW Chemical Foundation Scholar, Texas State University (1991-1995)
• Presidential Upper Division Scholar, Texas State University (1994-1995)
• ACS Polymer Education Committee Award for Organic Chemistry (1993)

Professional Activities

• Senior Fellow, NAI
• Member, AIChE
• Member, ACS
• Member, SIM
• Member, ASEE

Startups

Research Projects

• Protein engineering tools in immunology

  Protein engineering tools in immunology

  Protein engineering tools in immunology can be used as an unbiased and systematic means of identifying new targets, generating diagnostic and therapeutic reagents, and characterizing the basic biology of infectious disease.

  ×
• Cellular engineering of protein expression hosts

  Cellular engineering of protein expression hosts

  Cellular engineering of protein expression hosts provides the ability to modify proteins in a site specific and controlled fashion—something increasingly important for the development of therapeutic proteins. We are developing methods by which cells are genetically engineered to incorporate sugars on a recombinant protein in a site-specific sequence dependent manner. Once a sugar is positioned on a given protein, conventional chemical modification such as PEGlylation can be used to further modify the protein and improve its therapeutic properties.

  ×
• Immunogenicity prediction

  Immunogenicity prediction

  Immunogenicity prediction is an important means to control the safety of protein drugs, which can be recognized by the patient's immune system as foreign, inducing an adaptive immune response that can cause significant toxicity. We are developing approaches in which the immunogenicity of proteins can be assessed in vitro using protein engineering tools.

  ×
• Enzyme therapeutics

  Enzyme therapeutics

  Enzyme therapeutics are a potential means of addressing the emerging health care crisis resulting from drug resistant microbial pathogens. Efforts are focused on the redesign of antimicrobial proteins for enhanced bactericidal activity towards various clinically relevant targets. One facet of this work relates to complications associated with the genetic disease cystic fibrosis, and is being investigated in conjunction with the Cystic Fibrosis Foundation Research Development Program at The Geisel School of Medicine at Dartmouth.

  ×

Selected Publications

• Scanlon, T.C., Dostal, S.M., Griswold, K.E. A High Throughput Screen for Antibiotic Drug Discovery. Biotechnology & Bioengineering (2013), [Epub ahead of print]; PMID: 23955804
• Teneback, C.C., Scanlon, T.C., Wargo, M.J., Bement, J., Griswold, K.E., Leclair, L.W. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrobial Agents and Chemotherapy (2013), 57(11), pp. 5559–5564
• Lamppa, J.W., Tanyos, S.A., Griswold, K.E. Engineering Escherichia coli for Soluble Expression and Single Step Purification of Active Human Lysozyme. Journal of Biotechnology (2013), 164, pp. 1-8
• Choi Y., Griswold K.E., Bailey-Kellogg C. Structure-based Redesign of Proteins for Minimal T cell Epitope Content. Journal of Computational Chemistry (2013), 34(10), pp. 879-891
• Lamppa, J.W., Griswold, K.E. Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and Antibiotic Synergy. Antimicrobial Agents and Chemotherapy (2013), 57(1), pp. 137-145
• Osipovitch, D.C., Parker, A.S., Makokha, C.D., Desrosiers, J., Kett, W.C., Moise, L., Bailey-Kellogg, C., Griswold, K.E. Design and Analysis of Immune-Evading Enzymes for ADEPT Therapy. Protein Engineering, Design & Selection (2012), 25(10), pp. 613-624

Courses

• ENGG 260: Advances in Biotechnology

Videos

News

Thayer Teams Receive Funding in Second Cohort of Dartmouth Innovations Accelerator for Cancer
Jul 07, 2022

Lab Report: Treatment for Drug-Resistant Bacterial Infections
Mar 15, 2021

Sullivan and Griswold Elected Senior Members of the National Academy of Inventors
Feb 11, 2021

Dartmouth-led Team Engineers New Treatment for Drug-Resistant Bacterial Infections
Sep 02, 2020

NIH Funds Dartmouth Study of Cellular Disease Processes
Aug 12, 2016

Student Awarded 2016–17 Mazilu Engineering Research Fellowship
Apr 06, 2016

Dartmouth Researchers Engineer Drug Micro-factory to Attack Tumor
May 15, 2015

Dartmouth Investigators Develop Antibacterial Enzymes to Combat Drug-Resistant Bacterial Pathogens
Apr 06, 2015

Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models
Mar 26, 2015

Dartmouth Investigators Conduct Systematic Testing of Deimmunized Biotherapeutic Agents
Feb 06, 2015

DCCNE sponsors symposium on immuno targeting and delivery
Dec 04, 2013

Dartmouth undergraduate engineering students win first prize...twice!
Aug 14, 2013

Hitchcock Foundation funds lung-disease project
Jun 22, 2011

NCI Awards $12.8 Million to Dartmouth Center of Cancer Nanotechnology Excellence
Mar 06, 2011

Engineering Students Awarded Thayer School Fellowships
Mar 04, 2011

Dartmouth Engineer earns top ranking from CFF
Mar 04, 2011

In the News